Resalis Therapeutics

About:

Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche

Website: https://www.resalistherapeutics.com

Top Investors: Sanofi, Club degli Investitori, Italian Angels for Growth, Sunstone Life Science Ventures, Claris Ventures

Description:

Resalis Therapeutics changes the way metabolic diseases are treated by targeting a key regulator of pathways that contribute to obesity and fatty liver disease. RES-010, the company's flagship program, is being developed using its expertise in non-coding RNA drug modality and lipid metabolism to provide a safe and convenient treatment option with disease-modifying therapeutic effects, such as long-term weight loss and reduced hepatic steatosis. Resalis is rapidly moving RES-010 into clinical trials for a variety of metabolic disorders, backed by strong preclinical evidence.